Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non Operating Income (2023 - 2025)

Historic Non Operating Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $2.7 million.

  • Monte Rosa Therapeutics' Non Operating Income fell 80.32% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 3478.04%. This contributed to the annual value of $11.0 million for FY2024, which is 3236.11% up from last year.
  • Monte Rosa Therapeutics' Non Operating Income amounted to $2.7 million in Q3 2025, which was down 80.32% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Non Operating Income peaked at $4.5 million during Q2 2025, and registered a low of $1.6 million during Q4 2023.
  • In the last 3 years, Monte Rosa Therapeutics' Non Operating Income had a median value of $2.6 million in 2024 and averaged $2.7 million.
  • Data for Monte Rosa Therapeutics' Non Operating Income shows a peak YoY increase of 7252.32% (in 2025) and a maximum YoY decrease of 80.32% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Non Operating Income stood at $1.6 million in 2023, then soared by 63.44% to $2.6 million in 2024, then rose by 4.62% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $4.5 million for Q2 2025, and $3.7 million during Q1 2025.